BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

What are scientists scared of? Delve into three biotech sci-fi-inspired scenarios that might make you fear progress.

Cell therapy biotech Tolerance Bio has unveiled with ... our pioneering concepts in a rare disease and then assess proof-of-concept in multiple major indications, advancing these novel ...

However, the biotech has what it takes to be successful in the challenging gene-editing niche. This company might be worth far more than many realize. If I had to buy one share of any biotech with ...

Allison DeAngelis, who covers biotech startups and venture capital, is also the author of STAT’s annual report “Ranking Biotech’s Top Venture Capital Firms.” Biotech investors have been ...

Bright Minds Biosciences, which until this week had a lightly traded stock that traded at just over $1, tumbled in premarket trade on Wednesday following a meteoric rise. Bright Minds shares DRUG ...

Commissions do not affect our editors' opinions or evaluations. Biotech stocks are not for the faint of heart. These highly volatile equities can see stomach-churning price swings, driven by how ...

The company, which had filed two notices of intention to appoint administrators, bought by a Derbyshire counterpart ...

The broad field of biotechnology and applied microbiology covers topics on the manipulation of living organisms to make products or solve problems to meet human needs. Students in this field study ...

The partnership between Transgene and ProBioGen underscores a shared commitment to advancing the field of individualized medicine and to support manufacturing scalability and optimization.

India's biotechnology sector is witnessing remarkable ... providing crucial infrastructure for startups to develop proof-of-concept products. "Startups often face challenges in finding laboratory ...